Since the extraordinary general meeting of NeuroVive Pharmaceutical AB on Thursday, January 17, 2019 decided to issue a rights issue with a subscription period from January 23, 2019 until February 6, 2019, the Company wishes to remind of the company presentations NeuroVive gives in January 2019.
NeuroVive’s CEO Erik Kinnman will present the company and the business at the following events. For more information, see further under the respective links below.
Monday, 21 January Swedish Shareholders’ Association – Aktiekväll, theme Life Science
Stockholm Hotell Birger Jarl, Birger Jarlsgatan 61A, at 17.30
https://www.aktiespararna.se/aktiviteter/aktiekvallen-stockholm-21-januari
Tuesday, 22 January Swedish Shareholders’ Association – Aktiekväll
Gothenburgh Elite Park Avenue, Kungsportsavenyn 36, at 17.30
https://www.aktiespararna.se/aktiviteter/aktiekvallen-goteborg
Tuesday, 29 January Aktiedagen, Swedish Shareholders’ Association
Lund Medicon Village, Scheelevägen 2, 08.00 – 18.20
https://www.aktiespararna.se/aktiviteter/aktiedagen-lund-29-januari-0
For further information on the Company, a newly recorded interview with NeuroVive’s CEO Erik Kinnman is available on Cornelia News: http://cornelianews.com/c-talk/milstolpar-uppnadda-nu-tar-neurovive-in-124-miljoner-kr/.
The information was submitted for publication, through the agency of the contact person set out below, at 08.30 a.m. CET on 18 January 2019.
For more information please contact:
Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@neurovive.com
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@neurovive.com, www.neurovive.com
For news subscription, please visit http://www.neurovive.com/press-releases/subscription-page/
Follow us on LinkedIn
Subscribe to our YouTube channel
About NeuroVive
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio also consists of projects for genetic mitochondrial disorders, cancer and NASH. The company advances drugs for rare diseases through clinical development into the market. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).